Novo Nordisk Reports 22% Weight Loss in Early Subcutaneous Amycretin Trial
COPENHAGEN, Jan 24 - Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.Shares jumped on the release and traded up 10% in premarket trading.Amycretin targets the same gut hormone that Wegovy mimics, known as GLP-1, but also a pancreas hormone called amylin that affects hunger."The results seen in the trial support the weight